Early and intensive treatment: glycaemic control in type 2 diabetes

Abstract

References

1. Bailey CJ , Del Prato S , Eddy D. et al. Earlier intervention in type 2 diabetes: the case for achieving early and sustained glycaemic control. Int J Clin Pract 2005;59:1309–16.

2. Stratton IM , Adler AI , Neil HA. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405–12.

3. Gadde P , Vedel P , Larson N. et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383–93.

4. Saydah SH , Fradkin J , Cowie CC Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335–42.

5. Liebl A. Evaluation of risk factors for development of complications in type II diabetes in Europe. Diabetologia 2002;45:S23–S28.

6. Brown J , Nichols G Glycemic burden of oral agent failure in type 2 diabetes. Diabetes 2003;52(suppl 1):A61-2.

7. Diabetes UK. Diabetes Update, winter 2000.

8. UKPDS Group . UK Prospective Diabetes Study 6. Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. Diabetes Res 1990;13:1–11.

9. The DECODE Study Group . Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncar-diovascular diseases? Diabetes Care 2003;26:688–96.

10.

10. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group . Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643–53.

11.

11. Nathan DN , Buse JB , Davidson MB. et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006;49:1711–21.

12.

12. Canadian Diabetes Association . Clinical Practice Guidelines Expert Committee. Pharmacologic management of type 2 diabetes. Can J Diabetes 2003;27(suppl 2):S37–S42.

13.

13. American Diabetes Association Position Statement . Standards of medical care in diabetes. Diabetes Care 2005;28(suppl 1):S4–S36.

14.

14. European Diabetes Policy group . A desktop guide to type 2 diabetes mellitus. Diabetic Med 1999;16:716–30.

15.

15. International Diabetes Federation . Clinical Guidelines task force. Global guideline for type 2 diabetes. Brussels: International Diabetes Federation, 2005, pp 26–28.

16.

16. Canadian Diabetes Association . Clinical Practice Guidelines Expert Committee. Clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003;27(suppl 2):S18–S23.

17.

17. National Institute for Clinical Excellence . Clinical guideline G. Management of type 2 diabetes. Management of blood glucose. London, National Institute for Clinical Excellence, 2002.

18.

18. Joint British Societies . JBS 2 guidelines on prevention of cardiovascular disease. Heart 2005;91(suppl 5):1–52.

19.

19. American Association of Clinical Endocrinologists . Medical guidelines for the management of diabetes mellitus: the AACE system of intensive self-management- 2002 update. Endocrine Pract 2002;8(suppl 1):40–82.

20.

20. Latin American Diabetes Association (ALAD) . Guidelines for the diagnosis, control and treatment of type 2 diabetes mellitus. Rev Assoc Lat Diab 2000;8(suppl 1):101–67.

21.

21. Asian-Pacific Type 2 Diabetes Policy Group . Type 2 diabetes practical targets and treatments, 3rd edn. Sydney: Health Communications Australia, 2002.

22.

22. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus: metabolic and molecular implications for identifying diabetes genes. Diabetes Revs 1997;5:117–269.

23.

23. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003;46:3–19.

24.

24. Turner RC , Cull CA , Frighi V , Holman RR Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005–12.

25.

25. Dailey G , Kim MS , Lian JF Patient compliance and persistence with anti-hyperglycemic therapy: evaluation of a population of type 2 diabetic patients. J Int Med Res 2002;30:71–9.

26.

26. Bailey CJ.

Whence and whither the fixed-dose combination?

Diab Vasc Dis Res 2005;2:51–3.

27.

27. Day C. New therapies available for the treatment of type 2 diabetes. Eur Diabetes Nursing 2006;3:65–70.

28.

28. Krentz AJ , Bailey CJ Oral antidiabetic agents. Current role in type 2 diabetes mellitus. Drugs 2005;65:385–411.

29.

29. Bailey CJ. Drugs on the horizon for diabesity. Curr Diabetes Reps 2005;5:353–9.

30.

30. Green BD , Irwin N , Gault VA. et al. Development and therapeutic potential of incretin hormone analogues for type 2 diabetes. Br J Diabetes Vasc Dis 2005;5:134–40.

31.

31. Green B , Flatt PR , Bailey CJ Dipeptidyl peptidase IV inhibitors. A newly emerging drug class for the treatment of type 2 diabetes. Diab Vasc Dis Res 2006;3:159–65.

32.

32. Day C. Amylin analogue as an antidiabetic agent. Br J Diabetes Vasc Dis 2005;5:151–4.

33.

33. Day C , Bailey CJ Pharmacological approaches to reduce adiposity. Br J Diabetes Vasc Dis 2006;6:121–5.

34.

34. Scheen AJ , Finer N , Hollander P , Jansen MD. et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006; DOI: 10:1016/S0140-6736(06)69571-8.